PuSH - Publication Server of Helmholtz Zentrum München

62 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Habringer, S.* et al.: Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics. Theranostics 8, 369-383 (2018)
2.
Kessel, K.A. et al.: Cancer Clinical Trials - survey evaluating patient participation and attitude in an Oncology Center. Radiother. Oncol. 127, S50-S50 (2018)
3.
Kessel, K.A. et al.: Cancer clinical trials - Survey evaluating patient participation and acceptance in a university-based Comprehensive Cancer Center (CCC). Clin. Transl. Radiat. Oncol. 13, 44-49 (2018)
4.
Mangolini, M.* et al.: Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia. Nat. Commun. 9:3839 (2018)
5.
Eichner, R.* et al.: Immunomodulatory drugs destabilize CD98hc and LAT1 to interfere with amino acid transport and tumor metabolism. Oncol. Res. Treat. 40, 82-82 (2017)
6.
Garz, A.K.* et al.: Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations. Oncotarget 8, 108738-108759 (2017)
7.
Habringer, S.* et al.: CXCR4-directed peptide receptor radiotherapy with 177Lu-Pentixather effectively clears leukemia in patient-derived xenografts. Oncol. Res. Treat. 40, 214-214 (2017)
8.
Kessel, K.A. et al.: mHealth in oncology: A Patient survey evaluating the acceptance of app-assisted cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 99, E402-E402 (2017)
9.
Kessel, K.A. et al.: Mobile applications in oncology - a survey on evaluating the patient acceptance in a German Oncology Center: Final analysis. Strahlenther. Onkol. 193, S23-S24 (2017)
10.
Kessel, K.A. et al.: Mobile health in oncology: A patient survey about app-assisted cancer care. JMIR 5:e81 (2017)
11.
Habringer, S.* et al.: CXCR4-directed peptide receptor radiotherapy with 177Lu-Pentixather effectively clears leukemia in patient-derived xenografts. Oncol. Res. Treat. 39, 214-214 (2016)
12.
Höckendorf, U.* et al.: RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell 30, 75-91 (2016)
13.
Hoellein, A.* et al.: Serious outbreak of human metapneumovirus in patients with hematologic malignancies. Leuk. Lymphoma 57, 623-627 (2016)
14.
Kessel, K.A. et al.: Use of Complementary and Alternative Medicine (CAM) as part of the oncological treatment: Survey about patients' attitude towards CAM in a university-based oncology center in Germany. PLoS ONE 11:e0165801 (2016)
15.
Mall, S.* et al.: Immuno-PET imaging of engineered human T cells in tumors. Cancer Res. 76, 4113-4123 (2016)
16.
Spinner, S.* et al.: Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance. Leukemia 30, 1520-1530 (2016)
17.
Baumgart, A.* et al.: Opposing role of Notch1 and Notch2 in a KrasG12D-driven murine non-small cell lung cancer model. Oncogene 34, 578–588 (2015)
18.
Garz, A.-K.* et al.: The combination of crenolanib and azacitidine effectively targets leukemia-initiating cells in FLT3-ITD+ AML to overcome protection by the bone marrow niche. Oncol. Res. Treat. 38, 214 (2015)
19.
Garz, A.-K.* et al.: Azacitidine in combination with the selective FLT3 kinase inhibitor crenolanib effectively disrupts stromal protection of CD34+Leukemia-Initiating Cells (LIC) in FLT3-ITD+ Acute Myeloid Leukemia (AML). Blood 126 (2015)
20.
Habringer, S.* et al.: Very early functional in-vivo imaging to predict response to B cell receptor pathway targeting in lymphoma. Oncol. Res. Treat. 38, 99 (2015)